FY2025 EPS Estimates for PepGen Lifted by Leerink Partnrs

PepGen, Inc. (NASDAQ:PEPG) – Research analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for shares of PepGen in a research note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($2.74) per share for the year, up from their previous estimate of ($2.76). The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen’s Q4 2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.96) EPS and FY2027 earnings at ($3.46) EPS.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11.

Other equities research analysts have also recently issued research reports about the company. Guggenheim reaffirmed a “buy” rating and set a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Wedbush boosted their price objective on shares of PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. HC Wainwright upped their price objective on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

PepGen Stock Down 3.1%

Shares of PEPG opened at $4.74 on Monday. The firm has a market cap of $155.47 million, a price-to-earnings ratio of -1.68 and a beta of 1.95. The company’s fifty day moving average is $4.00 and its 200-day moving average is $2.29. PepGen has a 12 month low of $0.88 and a 12 month high of $6.85.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Viking Global Investors LP boosted its holdings in PepGen by 134.9% in the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after purchasing an additional 2,000,000 shares during the period. Deep Track Capital LP acquired a new stake in shares of PepGen in the third quarter valued at approximately $5,544,000. Vanguard Group Inc. boosted its stake in shares of PepGen by 88.7% in the third quarter. Vanguard Group Inc. now owns 1,768,356 shares of the company’s stock valued at $8,170,000 after buying an additional 831,333 shares during the period. Woodline Partners LP bought a new stake in shares of PepGen in the first quarter valued at approximately $1,097,000. Finally, Adage Capital Partners GP L.L.C. grew its position in PepGen by 68.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock worth $1,897,000 after buying an additional 550,000 shares in the last quarter. Institutional investors own 58.01% of the company’s stock.

Insider Buying and Selling at PepGen

In related news, major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of PepGen stock in a transaction on Tuesday, September 30th. The stock was purchased at an average cost of $3.20 per share, with a total value of $640,000.00. Following the completion of the transaction, the insider directly owned 4,955,388 shares in the company, valued at $15,857,241.60. This trade represents a 4.21% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.